Cargando…

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study

Background: Data on the neuropsychological outcomes after receiving direct-acting antivirals (DAAs) among chronic hepatitis C (CHC) patients have not been well-documented. Aim: This study aimed to evaluate the difference in incidence of neuropsychological disorders (NPDs) after treatment completion...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yu, Chen, Chung-Yu, Yu, Hsien-Chung, Lin, Pei-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394649/
https://www.ncbi.nlm.nih.gov/pubmed/37538181
http://dx.doi.org/10.3389/fphar.2023.1191843
_version_ 1785083419374387200
author Fang, Yu
Chen, Chung-Yu
Yu, Hsien-Chung
Lin, Pei-Chin
author_facet Fang, Yu
Chen, Chung-Yu
Yu, Hsien-Chung
Lin, Pei-Chin
author_sort Fang, Yu
collection PubMed
description Background: Data on the neuropsychological outcomes after receiving direct-acting antivirals (DAAs) among chronic hepatitis C (CHC) patients have not been well-documented. Aim: This study aimed to evaluate the difference in incidence of neuropsychological disorders (NPDs) after treatment completion between CHC patients receiving interferon (IFN) therapy and DAA therapy. Methods: A nationwide retrospective cohort study was performed using Taiwan’s National Health Insurance Research Database (NHIRD) between 2010 and 2018. CHC patients without pre-existing mental disorders were included and divided into the treatment (Tx)-naïve DAA group, retreatment (re-Tx) DAA group, and Tx-naïve IFN group based on their HCV therapy. Propensity score matching was used to balance baseline differences between groups. The primary outcome was the incidence of NPDs during 6 months after completion of therapy. Results: After one-to-one matching, there were 6,461 pairs of patients selected from the Tx-naïve DAA group and Tx-naïve IFN group and 3,792 pairs from the re-Tx DAA group and Tx-naïve IFN group. A lower incidence of NPDs was observed in the Tx-naïve DAA group than in the Tx-naïve IFN group (HR = 0.72, 95% CI = 0.55–0.94, and p = 0.017). The risk of NPDs did not differ between the re-Tx DAA group and the Tx-naïve IFN group (HR = 0.74, 95% CI: 0.52–1.05, and p = 0.092). Conclusion: DAA therapy was associated with lower risk of NPDs when compared with IFN therapy among Tx-naïve CHC patients in a 6-month period after treatment completion, especially among the patients less than 65 years, male gender, and cirrhosis.
format Online
Article
Text
id pubmed-10394649
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103946492023-08-03 Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study Fang, Yu Chen, Chung-Yu Yu, Hsien-Chung Lin, Pei-Chin Front Pharmacol Pharmacology Background: Data on the neuropsychological outcomes after receiving direct-acting antivirals (DAAs) among chronic hepatitis C (CHC) patients have not been well-documented. Aim: This study aimed to evaluate the difference in incidence of neuropsychological disorders (NPDs) after treatment completion between CHC patients receiving interferon (IFN) therapy and DAA therapy. Methods: A nationwide retrospective cohort study was performed using Taiwan’s National Health Insurance Research Database (NHIRD) between 2010 and 2018. CHC patients without pre-existing mental disorders were included and divided into the treatment (Tx)-naïve DAA group, retreatment (re-Tx) DAA group, and Tx-naïve IFN group based on their HCV therapy. Propensity score matching was used to balance baseline differences between groups. The primary outcome was the incidence of NPDs during 6 months after completion of therapy. Results: After one-to-one matching, there were 6,461 pairs of patients selected from the Tx-naïve DAA group and Tx-naïve IFN group and 3,792 pairs from the re-Tx DAA group and Tx-naïve IFN group. A lower incidence of NPDs was observed in the Tx-naïve DAA group than in the Tx-naïve IFN group (HR = 0.72, 95% CI = 0.55–0.94, and p = 0.017). The risk of NPDs did not differ between the re-Tx DAA group and the Tx-naïve IFN group (HR = 0.74, 95% CI: 0.52–1.05, and p = 0.092). Conclusion: DAA therapy was associated with lower risk of NPDs when compared with IFN therapy among Tx-naïve CHC patients in a 6-month period after treatment completion, especially among the patients less than 65 years, male gender, and cirrhosis. Frontiers Media S.A. 2023-07-19 /pmc/articles/PMC10394649/ /pubmed/37538181 http://dx.doi.org/10.3389/fphar.2023.1191843 Text en Copyright © 2023 Fang, Chen, Yu and Lin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fang, Yu
Chen, Chung-Yu
Yu, Hsien-Chung
Lin, Pei-Chin
Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title_full Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title_fullStr Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title_full_unstemmed Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title_short Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
title_sort neuropsychiatric disorders in chronic hepatitis c patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394649/
https://www.ncbi.nlm.nih.gov/pubmed/37538181
http://dx.doi.org/10.3389/fphar.2023.1191843
work_keys_str_mv AT fangyu neuropsychiatricdisordersinchronichepatitiscpatientsafterreceivinginterferonordirectactingantiviralsanationwidecohortstudy
AT chenchungyu neuropsychiatricdisordersinchronichepatitiscpatientsafterreceivinginterferonordirectactingantiviralsanationwidecohortstudy
AT yuhsienchung neuropsychiatricdisordersinchronichepatitiscpatientsafterreceivinginterferonordirectactingantiviralsanationwidecohortstudy
AT linpeichin neuropsychiatricdisordersinchronichepatitiscpatientsafterreceivinginterferonordirectactingantiviralsanationwidecohortstudy